An overview of the current status of engineered therapeutic monoclonal antibodies
International Pharmacy Acta,
Vol. 2 No. 1 (2019),
16 December 2019
,
Page 2e9:1-10
https://doi.org/10.22037/ipa.v2i1.22134
Abstract
Since the commercialization of the first therapeutic monoclonal antibody (mAb) product in 1986, this class of biopharmaceutical products have grown significantly. Due to the enhanced antigen binding and reduced cellular toxicity, they result in more efficacy in treatment of variety of diseases. The global sales of mAbs which was 95.1 b$ in 2017 have grown annually due to the dramatic increase in cancer and severe diseases rates and are estimated to reach 131.33 b$ by 2023, this represents a clear accelerating trend with more than 5.53% growth. In this review, we discuss some of these mAbs which have been approved by the FDA as well as others that are experiencing or being evaluated in clinical phases. Global sales of some monoclonal antibodies in 2016 are also considered, suggesting a significant increase in sales of mAbs over the years ahead.
- Monoclonal Antibody
- Market; Phage display
- ScFv Antibodies
How to Cite
References
Carter PJ. Potent antibody therapeutics by design. Nature Rev Immunol. 2006;6:343–57.
Dimitrov DS, Marks JD. Therapeutic antibodies: Current state and future trends—is a paradigm change coming soon? Methods Mol Biol. 2008;525:1–27.
Leader B, Baca QJ, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nature Rev Drug Discov. 2008;7:21–39.
Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Monoclonal antibodies in cancer therapy. OncoImmunology. 2012;1(1):28-37.
Hale JEJIjop. Advantageous uses of mass spectrometry for the quantification of proteins. 2013;2013.
Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009;27 Suppl 6(Suppl 6):G38-46.
Yokoyama WM, Christensen M, Santos GD, Miller D, Ho J, Wu T, et al. Production of Monoclonal Antibodies. 2013;102(1):2.5.1-2.5.29.
Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically functional bacterial
plasmids in vitro. Proc Natl Acad Sci USA. 1973;70:3240-4.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7.
Hutchinson CA, Philips S, Edgell MH, Gillam S, Jahnke P, Smith M. Mutagenesis at a specific position in a DNA sequence. J Biol Chem. 1978;253:6551-60.
Zoller MJ, Smith M. Oligonucleotide-directed mutagenesis using M13-derived vectors: An efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acids Res. 1982;10:6487-500.
Dalbadie-McFarland G, Cohen LW, Riggs AD, Morin C, Itakura K, Richards JH. Oligonucleotide-directed mutagenesis as a general and powerful method for studies of protein function. Proc Natl Acad Sci USA 1982; 79:6409-13.
Smith GP. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315-7.
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: The polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986;51(pt. 1):263-73.
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS. Sequences of proteins of immunological interest. 1987;Washington, D.C.: U.S. Department of Health and Human Services. Publ. No. 91-3242.
Neuberger MS. Expression and regulation of immunoglobulin heave chain gene transfected into lymphoid cells. EMBO J. 1983;1373-1378.
Neuberger MS, Williams GT. Construction of novel antibodies by use of DNA transfection: Design of plasmid vectors. Philos Trans R Soc London A. 1986;317:425-32.
Thistlethwaite JR, Gaber AO, Haag BW, Aronson AJ, Broelsch CE, Stuart JK, et al. OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation. 1987;43:176-84.
Ecker DM, Jones SD, Levine HL, editors. The therapeutic monoclonal antibody market. MAbs; 2015: Taylor & Francis.
Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the'high-hanging fruit'. Nature Reviews Drug Discovery. 2018;17(3):197.
Santos MLd, Quintilio W, Manieri TM, Tsuruta LR, Moro AMJBJoPS. Advances and challenges in therapeutic monoclonal antibodies drug development. 2018;54(SPE).
Shire SJ, Gombotz WR, Bechtold-Peters K, Andya J. Current Trends in Monoclonal Antibody Development and Manufacturing. Gombotz WR, Shire SJ, editors. New York: Springer; 2010. 351 p.
Saldanha JW. Humanization of Recombinant Antibodies. New York: Cambridge University Press.; 2009.
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of Sciences of the USA. 1984;81:6851-5.
Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric
mouse/human antibody. Nature. 1984;312:643-6.
Jones PT, Dear PH, Foote J, Nueuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522-5.
Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature biotechnology. 2005;23(9):1126-36.
Hentrich C, Ylera F, Frisch C, Ten Haaf A, Knappik A. Monoclonal Antibody Generation by Phage Display: History, State-of-the-Art, and Future. Handbook of Immunoassay Technologies: Elsevier; 2018. p. 47-80.
Teixeira D, Gonzalez-Pajuelo M. Phage Display Technology for Selection of Antibody Fragments. Biomedical Applications of Functionalized Nanomaterials: Elsevier; 2018. p. 67-88.
Evans JB, Syed BA. Next-generation antibodies. Nature Reviews Drug Discovery. 2014.
Wu J, Fu J, Zhang M, Liu DJJoh, oncology. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. 2015;8(1):104.
Wendtner C-M. Otlertuzumab more than a TRU (E) toddler in CLL? Blood. 2014;123(9):1282-4.
Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clinical pharmacology: advances and applications. 2013;5(Suppl 1):5.
De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends in biotechnology. 2014;32(5):263-70.
Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM. Nanobody-based cancer therapy of solid tumors. Nanomedicine. 2015;10(1):161-74.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery. 2017;16(5):315.
Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al. Antibody–drug conjugates: current status and future directions. Drug discovery today. 2014;19(7):869-81.
Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clinical Cancer Research. 2011;17(20):6406-16.
Teicher BA. Antibody Drug and Radionuclide Conjugates for GI Cancers. Immunotherapy for Gastrointestinal Cancer: Springer; 2017. p. 79-99.
Soltani S, Davoodabadi A, Farahani A, Dastranj M, Amini M, Momenifar N, et al. A review on the types of immunotoxins and their use in cancer treatment. Tehran University Medical Journal TUMS Publications. 2018;76(1):12-8.
Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nature Reviews Cancer. 2006;6(7):559-65.
Mazor R, Onda M, Pastan I. Immunogenicity of therapeutic recombinant immunotoxins. Immunological reviews. 2016;270(1):152-64.
Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology. 2017;6(12):e1371896.
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews Cancer. 2007;7(2):95-106.
Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(2):e27297.
Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997;15:146-56.
Fishwild DM, O’Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnol. 1996;14(7):845-51.
Bruggemann M, Willimas GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. Journal of Experimental Medicine. 1987;166:1351-61.
Kim SJ, Park Y, Hong HJ. Antibody Engineering for the Development of Therapeutic Antibodies Molecules and Cells. 2005;20(1):17-29.
Strohl WR. Therapeutic monoclonal antibodies: past, present, and future. Therapeutic Monoclonal Antibodies: From Bench to Clinic. 2009:1-50.
Hammers CM, Stanley JR. Antibody Phage Display: Technique and Applications. Journal of Investigative Dermatology. 2014;134(2):e17.
Frenzel A, Schirrmann T, Hust M, editors. Phage display-derived human antibodies in clinical development and therapy. MAbs; 2016: Taylor & Francis.
- Abstract Viewed: 270 times
- PDF Downloaded: 358 times